{"id":8521,"date":"2013-09-10T06:18:12","date_gmt":"2013-09-10T06:18:12","guid":{"rendered":"http:\/\/www.ilmelanoma.com\/?p=8521"},"modified":"2013-09-10T06:18:37","modified_gmt":"2013-09-10T06:18:37","slug":"study-moffitt-cancer-center-offer-hope-people-melanoma","status":"publish","type":"post","link":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/","title":{"rendered":"A new study at Moffitt Cancer Center could offer hope to people with melanoma"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Abstract from PLOS ONE<\/strong>: <a title=\"melanoma therapy pv10\" href=\"https:\/\/www.plosone.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pone.0068561\">Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer\u00a0\u00a0Paul Toomey,\u00a0\u00a0Krithika Kodumudi, Amy Weber,\u00a0Lisa Kuhn,\u00a0\u00a0Ellen Moore,\u00a0Amod A. Sarnaik, Shari Pilon-Thomas\u00a0<\/a><\/p>\n<p style=\"text-align: justify;\">Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB\/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions. In a murine model of melanoma, B16 cells were injected into C57BL\/6 mice to establish one subcutaneous tumor and multiple lung lesions. Treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases. Anti-tumor immune responses were measured in splenocytes collected from mice treated with IL PBS or PV-10.<\/p>\n<p><a title=\"melanoma therapy PV10\" href=\"https:\/\/www.plosone.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pone.0068561\">Read more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abstract from PLOS ONE: Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer\u00a0\u00a0Paul Toomey,\u00a0\u00a0Krithika Kodumudi, Amy Weber,\u00a0Lisa Kuhn,\u00a0\u00a0Ellen Moore,\u00a0Amod A. Sarnaik, Shari Pilon-Thomas\u00a0 Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine [&hellip;]<\/p>\n","protected":false},"author":13,"featured_media":7505,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[209,211],"tags":[678,328,677,679,680,681,676],"class_list":["post-8521","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-spotlight","tag-hope","tag-melanoma-en","tag-melanoma-therapy","tag-patients","tag-pv10-en","tag-rosa-bengala","tag-therapy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>A new study at Moffitt Cancer Center could offer hope to people with melanoma: PV10<\/title>\n<meta name=\"description\" content=\"Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB\/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions. In a murine model of melanoma, B16 cells were injected into C57BL\/6 mice to establish one subcutaneous tumor and multiple lung lesions. Treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases. Anti-tumor immune responses were measured in splenocytes collected from mice treated with IL PBS or PV-10.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dott.ssa Matilde Angelotti\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/\"},\"author\":{\"name\":\"Dott.ssa Matilde Angelotti\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/person\/0587ef084351b31b95f697a5f7762f32\"},\"headline\":\"A new study at Moffitt Cancer Center could offer hope to people with melanoma\",\"datePublished\":\"2013-09-10T06:18:12+00:00\",\"dateModified\":\"2013-09-10T06:18:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/\"},\"wordCount\":181,\"publisher\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/09\/P11-07-12_19.011.jpg\",\"keywords\":[\"hope\",\"melanoma\",\"melanoma therapy\",\"patients\",\"pv10\",\"Rosa Bengala\",\"therapy\"],\"articleSection\":[\"News\",\"Spotlight\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/\",\"url\":\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/\",\"name\":\"A new study at Moffitt Cancer Center could offer hope to people with melanoma: PV10\",\"isPartOf\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/09\/P11-07-12_19.011.jpg\",\"datePublished\":\"2013-09-10T06:18:12+00:00\",\"dateModified\":\"2013-09-10T06:18:37+00:00\",\"description\":\"Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB\/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions. In a murine model of melanoma, B16 cells were injected into C57BL\/6 mice to establish one subcutaneous tumor and multiple lung lesions. Treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases. Anti-tumor immune responses were measured in splenocytes collected from mice treated with IL PBS or PV-10.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#primaryimage\",\"url\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/09\/P11-07-12_19.011.jpg\",\"contentUrl\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/09\/P11-07-12_19.011.jpg\",\"width\":1600,\"height\":1200,\"caption\":\"Lentigo Maligna Melanoma\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#website\",\"url\":\"https:\/\/www.ilmelanoma.com\/en\/\",\"name\":\"Il Melanoma\",\"description\":\"la guida alla conoscenza, prevenzione e cura del melanoma\",\"publisher\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ilmelanoma.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#organization\",\"name\":\"Il Melanoma\",\"url\":\"https:\/\/www.ilmelanoma.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png\",\"contentUrl\":\"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png\",\"width\":300,\"height\":29,\"caption\":\"Il Melanoma\"},\"image\":{\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/person\/0587ef084351b31b95f697a5f7762f32\",\"name\":\"Dott.ssa Matilde Angelotti\",\"description\":\"Dott.ssa Matilde Angelotti- Medico Chirurgo - Esame dermatoscopico per l\u2019analisi dei nevi\",\"url\":\"https:\/\/www.ilmelanoma.com\/en\/author\/nicola-angelotti\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A new study at Moffitt Cancer Center could offer hope to people with melanoma: PV10","description":"Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB\/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions. In a murine model of melanoma, B16 cells were injected into C57BL\/6 mice to establish one subcutaneous tumor and multiple lung lesions. Treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases. Anti-tumor immune responses were measured in splenocytes collected from mice treated with IL PBS or PV-10.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/","twitter_misc":{"Written by":"Dott.ssa Matilde Angelotti","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#article","isPartOf":{"@id":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/"},"author":{"name":"Dott.ssa Matilde Angelotti","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/person\/0587ef084351b31b95f697a5f7762f32"},"headline":"A new study at Moffitt Cancer Center could offer hope to people with melanoma","datePublished":"2013-09-10T06:18:12+00:00","dateModified":"2013-09-10T06:18:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/"},"wordCount":181,"publisher":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#organization"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/09\/P11-07-12_19.011.jpg","keywords":["hope","melanoma","melanoma therapy","patients","pv10","Rosa Bengala","therapy"],"articleSection":["News","Spotlight"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/","url":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/","name":"A new study at Moffitt Cancer Center could offer hope to people with melanoma: PV10","isPartOf":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#primaryimage"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/09\/P11-07-12_19.011.jpg","datePublished":"2013-09-10T06:18:12+00:00","dateModified":"2013-09-10T06:18:37+00:00","description":"Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB\/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions. In a murine model of melanoma, B16 cells were injected into C57BL\/6 mice to establish one subcutaneous tumor and multiple lung lesions. Treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases. Anti-tumor immune responses were measured in splenocytes collected from mice treated with IL PBS or PV-10.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/study-moffitt-cancer-center-offer-hope-people-melanoma\/#primaryimage","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/09\/P11-07-12_19.011.jpg","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2012\/09\/P11-07-12_19.011.jpg","width":1600,"height":1200,"caption":"Lentigo Maligna Melanoma"},{"@type":"WebSite","@id":"https:\/\/www.ilmelanoma.com\/en\/#website","url":"https:\/\/www.ilmelanoma.com\/en\/","name":"Il Melanoma","description":"la guida alla conoscenza, prevenzione e cura del melanoma","publisher":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ilmelanoma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ilmelanoma.com\/en\/#organization","name":"Il Melanoma","url":"https:\/\/www.ilmelanoma.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","contentUrl":"https:\/\/www.ilmelanoma.com\/wp-content\/uploads\/2023\/06\/logo-melanoma-azzurro.png","width":300,"height":29,"caption":"Il Melanoma"},"image":{"@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.ilmelanoma.com\/en\/#\/schema\/person\/0587ef084351b31b95f697a5f7762f32","name":"Dott.ssa Matilde Angelotti","description":"Dott.ssa Matilde Angelotti- Medico Chirurgo - Esame dermatoscopico per l\u2019analisi dei nevi","url":"https:\/\/www.ilmelanoma.com\/en\/author\/nicola-angelotti\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/8521","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/comments?post=8521"}],"version-history":[{"count":2,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/8521\/revisions"}],"predecessor-version":[{"id":8523,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/posts\/8521\/revisions\/8523"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media\/7505"}],"wp:attachment":[{"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/media?parent=8521"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/categories?post=8521"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ilmelanoma.com\/en\/wp-json\/wp\/v2\/tags?post=8521"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}